BRIDGEBIO PHARMA INC
NASDAQ: BBIO (BridgeBio Pharma, Inc.)
Last update: 2 hours ago68.56
-2.55 (-3.59%)
| Previous Close | 71.11 |
| Open | 70.64 |
| Volume | 1,723,846 |
| Avg. Volume (3M) | 2,710,870 |
| Market Cap | 13,291,237,376 |
| Price / Sales | 28.45 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Operating Margin (TTM) | -89.00% |
| Diluted EPS (TTM) | -3.56 |
| Quarterly Revenue Growth (YOY) | -44.80% |
| Current Ratio (MRQ) | 4.57 |
| Operating Cash Flow (TTM) | -500.42 M |
| Levered Free Cash Flow (TTM) | -261.20 M |
| Return on Assets (TTM) | -48.27% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | BridgeBio Pharma, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 1.0 |
| Technical Moving Averages | -5.0 |
| Technical Oscillators | -3.5 |
| Average | -0.88 |
|
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 4.97% |
| % Held by Institutions | 98.14% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Viking Global Investors Lp | 31 Dec 2025 | 14,393,934 |
| Kohlberg Kravis Roberts & Co. L.P. | 31 Dec 2025 | 13,260,971 |
| Janus Henderson Group Plc | 31 Dec 2025 | 11,000,457 |
| Farallon Capital Management Llc | 31 Dec 2025 | 8,998,463 |
| Aisling Capital Management Lp | 31 Dec 2025 | 5,089,611 |
| Frazier Life Sciences Management, L.P. | 31 Dec 2025 | 3,545,557 |
| Brooklands Fund Management Ltd | 31 Dec 2025 | 2,750,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 125.00 (Evercore ISI Group, 82.32%) | Buy |
| Median | 98.00 (42.94%) | |
| Low | 81.00 (Oppenheimer, 18.15%) | Buy |
| Average | 98.71 (43.98%) | |
| Total | 7 Buy | |
| Avg. Price @ Call | 70.23 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 10 Mar 2026 | 94.00 (37.11%) | Buy | 74.32 |
| Evercore ISI Group | 25 Feb 2026 | 125.00 (82.32%) | Buy | 66.54 |
| Morgan Stanley | 25 Feb 2026 | 98.00 (42.94%) | Buy | 66.54 |
| Oppenheimer | 25 Feb 2026 | 81.00 (18.14%) | Buy | 66.54 |
| 13 Feb 2026 | 83.00 (21.06%) | Buy | 75.25 | |
| Truist Securities | 25 Feb 2026 | 95.00 (38.56%) | Buy | 66.54 |
| HC Wainwright & Co. | 17 Feb 2026 | 100.00 (45.86%) | Buy | 75.85 |
| Wells Fargo | 13 Feb 2026 | 98.00 (42.94%) | Buy | 75.25 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |